Ticker: LUNG

Pulmonx Corporation (NASDAQ: LUNG) has released its financial results for the second quarter of 2025, demonstrating growth in revenue but continuing to incur significant losses. The company specializes in minimally invasive treatments for severe emphysema using its flagship product, the Zephyr Va...